These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19507008)

  • 21. Evaluating drug delivery with salt formation: Drug disproportionation studied in situ by ATR-FTIR imaging and Raman mapping.
    Ewing AV; Wray PS; Clarke GS; Kazarian SG
    J Pharm Biomed Anal; 2015; 111():248-56. PubMed ID: 25910459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of sertraline salt form on the oxidative stability in powder blends.
    Hsieh YL; Yu W; Xiang Y; Pan W; Waterman KC; Shalaev EY; Shamblin SL; Taylor LS
    Int J Pharm; 2014 Jan; 461(1-2):322-30. PubMed ID: 24325937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salt Stability - The Effect of pHmax on Salt to Free Base Conversion.
    Hsieh YL; Merritt JM; Yu W; Taylor LS
    Pharm Res; 2015 Sep; 32(9):3110-8. PubMed ID: 25874534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystalline solid dispersion-a strategy to slowdown salt disproportionation in solid state formulations during storage and wet granulation.
    Nie H; Xu W; Taylor LS; Marsac PJ; Byrn SR
    Int J Pharm; 2017 Jan; 517(1-2):203-215. PubMed ID: 27979765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of In-Situ-Generated Moisture on Disproportionation of Pharmaceutical Salt.
    Weldeab AO; McElderry JD; Lin Y
    Mol Pharm; 2023 Jan; 20(1):561-571. PubMed ID: 36524757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation.
    Mohan S; Li Y; Chu K; De La Paz L; Sperger D; Shi B; Foti C; Rucker V; Lai C
    Mol Pharm; 2024 May; 21(5):2590-2605. PubMed ID: 38656981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case study where pharmaceutical salts were used to address the issue of low in vivo exposure.
    Sigfridsson K; Ulvinge ML; Svensson L; Granath AK
    Drug Dev Ind Pharm; 2019 Feb; 45(2):202-211. PubMed ID: 30256689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physical stability of salts of weak bases in the solid-state.
    Stephenson GA; Aburub A; Woods TA
    J Pharm Sci; 2011 May; 100(5):1607-17. PubMed ID: 21374599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug.
    Greco K; Mcnamara DP; Bogner R
    J Pharm Sci; 2011 Jul; 100(7):2755-68. PubMed ID: 21328581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salt formation to improve drug solubility.
    Serajuddin AT
    Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of using physiologically relevant volume of dissolution medium to correlate the oral exposure of formulations of BMS-480188 mesylate.
    Gu CH; Gandhi RB; Tay LK; Zhou S; Raghavan K
    Int J Pharm; 2004 Jan; 269(1):195-202. PubMed ID: 14698591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of Microenvironmental Acidity: A Strategy to Mitigate Salt Disproportionation in Drug Product Environment.
    Koranne S; Lalge R; Suryanarayanan R
    Mol Pharm; 2020 Apr; 17(4):1324-1334. PubMed ID: 32142293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salt stability--effect of particle size, relative humidity, temperature and composition on salt to free base conversion.
    Hsieh YL; Taylor LS
    Pharm Res; 2015 Feb; 32(2):549-61. PubMed ID: 25145335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Lipophilic Salt Form to Enhance the Lipid Solubility and Certain Biopharmaceutical Properties of Lapatinib.
    Singh N; Chakravarti R; Das A; Gupta S; Ghosh D; Datta P
    Mol Pharm; 2024 Aug; 21(8):3921-3935. PubMed ID: 38935681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug.
    Li S; Doyle P; Metz S; Royce AE; Serajuddin AT
    J Pharm Sci; 2005 Oct; 94(10):2224-31. PubMed ID: 16136556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of counterion on the chemical stability of crystalline salts of procaine.
    Guerrieri P; Jarring K; Taylor LS
    J Pharm Sci; 2010 Sep; 99(9):3719-30. PubMed ID: 19967781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disproportionation of the calcium salt of atorvastatin in the presence of acidic excipients.
    Christensen NP; Rantanen J; Cornett C; Taylor LS
    Eur J Pharm Biopharm; 2012 Oct; 82(2):410-6. PubMed ID: 22824098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts. I: Phenazopyridine.
    Serajuddin AT; Jarowski CI
    J Pharm Sci; 1985 Feb; 74(2):142-7. PubMed ID: 3989682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement and Accurate Interpretation of the Solubility of Pharmaceutical Salts.
    He Y; Ho C; Yang D; Chen J; Orton E
    J Pharm Sci; 2017 May; 106(5):1190-1196. PubMed ID: 28153596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Throughput Raman Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs.
    Chen X; Stoneburner K; Ladika M; Kuo TC; Kalantar TH
    Appl Spectrosc; 2015 Nov; 69(11):1271-80. PubMed ID: 26647050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.